In the spring, five patients with sickle cell disease began treatment with Casgevy, the first FDA-approved CRISPR-Cas9 gene editing treatment. The therapy—which involves removing blood stem ...

In December 2023, through the development efforts of CRISPR Therapeutics and Vertex Pharmaceuticals, their decades-long ...

Doctors harvest stem cells from the patient’s bone marrow and then send them off to a lab, where CRISPR is used to turn up the production of another, functional version of haemoglobin. This version is ...

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

A new review in Engineering reveals that CRISPR technologies are revolutionizing regenerative medicine. Scientists from ...

Why are CRISPR companies not OK ... and the approval of a non-opioid pain drug from Vertex Pharmaceuticals. Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT ...

But for CRISPR to transform medicine it will have to ... And America’s Food and Drug Administration (FDA) has agreed to lower its stringent regulation standards so that companies can re-use ...

CRISPR technology, driven by Cas9, redefines gene editing, facilitating targeted DNA modifications that advance genetic ...

Tulane University researchers have developed a CRISPR-based test that diagnoses Pneumocystis jirovecii pneumonia (PJP)—a life-threatening fungal infection primarily affecting children and ...

In terms of liquidity and interest, the mean open interest for CRISPR Therapeutics options trades today is 628.14 with a total volume of 1,152.00.

CRISPR Therapeutics AG ( NASDAQ: CRSP) TD Cowen 45th Annual Healthcare Conference March 3, 2025 10:30 AM ET ...